$MTNB

Matinas BioPharma Holdings, Inc. (MTNB) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. false 0001582554 0001582554 2026-07-23 2026-07-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Repor

Healthcare stocks moved on multiple FDA and EU updates. Novartis (NVS) won FDA approval for Fabhalta in IgA nephropathy; Merck (MRK) got FDA nod for LIPFENDRA and KEYTRUDA+Padcev in bladder cancer; Novo Nordisk (NVO) received EU approval for oral Wegovy. Lilly (LLY) agreed to buy AtaiBeckley for $6.75/share plus up to $2.50 CVR.

Matinas BioPharma (MTNB) will merge with GH Power Inc. to form GH Power International, a NYSE-listed clean energy and green hydrogen company, under a definitive agreement. Matinas also agreed to sell its LNC platform and lead antifungal MAT2203 to Azurity Pharmaceuticals for $4M upfront, up to $17.5M milestones, and mid-single-digit royalties.

GH Power Inc. said it agreed to combine with Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) in a deal expected to create a NYSE-listed clean energy and critical minerals company. GH Power’s modular reactor tech would be scaled for hydrogen, heat, power, and alumina. A PIPE of at least $15.0M is planned, and the deal is expected to close in Q4 2026.

Matinas BioPharma Holdings, Inc. (MTNB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-2.1 2 ex2-1.htm EX-2.1 Exhibit 2.1 BUSINESS COMBINATION AGREEMENT by and among GH Power Inc. , as GH Power, 1001550000 ONTARIO INC., as Pubco, 1001550002 ONTARIO INC., as Merger Sub A, MATINAS BIOPHARMA HOLDINGS, INC., as Matinas, and MBH MERGER SUB, INC., as Merger Sub B Date

Matinas BioPharma (NYSE American: MTNB) said it received a June 24, 2026 NYSE American notice for non-compliance with continued listing equity standards. The company reported stockholders’ equity of $3.02 million as of March 31, 2026 and losses in five of its last fiscal years, and previously $4.83 million as of Dec. 31, 2025. NYSE American accepted its May 4, 2026 compliance plan, granting a plan period through Oct. 2, 2027, with quarterly monitoring; delisting proceedings could follow if progr

Matinas Biopharma Holdings’ short interest fell sharply in May, dropping to 387 shares as of May 15 from 4,431 shares on April 30, a 91.3% decrease, according to the report. The stock traded at $0.81 mid-day Friday. DRW Securities LLC bought 46,374 shares in Q4, worth about $27,000, per SEC disclosure.